BackUroGen Pharma Overview

UroGen Pharma Net Tangible Assets

UroGen Pharma's net tangible assets is $-130M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-132.40M
41.79% YoYΔ $-39.02M vs prior year quarter

Peer trimmed avg / median

Loading

UroGen Pharma Net Tangible Assets History

Loading

UroGen Pharma vs. peers: Net Tangible Assets Comparison

Loading

UroGen Pharma Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

UroGen Pharma (URGN) FAQ

As of the most recent data (June 2026), URGN shows a net tangible assets of $-130M. That compares with $-93M in the prior-year period — down 41.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, URGN's net tangible assets is now $-130M (was $-93M) — a 41.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether UroGen Pharma is outperforming or lagging.

Tracking URGN's net tangible assets over time shows whether UroGen Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-130M That compares with $-93M in the prior-year period — down 41.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has UroGen Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $-130M) with ownership activity and broader fundamentals.

UroGen Pharma's net tangible assets is $-130M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.